Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00911053 · ClinicalTrials.gov registry record · NA
Melatonin for Circadian Sleep Disorders in the Blind
A NA study, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- NA
- Development phase
- 59
- Enrollment target
NCT00911053: Clinical Trial NA study, sponsored by Oregon Health and Science University.
NCT00911053 is a NA study that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 59 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00911053, a NA study, was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
Study Summary
This research project consists of a three part study with five embedded sub studies. The first study phase identifies "body rhythms" of sleepiness/wakefulness and of melatonin levels for each subject (including sub-study 1). The second study phase identifies the optimum dose and timing of melatonin for regulating each individual's 24-hour sleep/waking cycle (including sub-study 2). The third study phase introduces a new independent variable, light (including sub-studies 3 and 4). Sub-study 5 is an optional longitudinal study. Sub-study 1 looks at how keeping a regular sleep schedule affects the body's natural rhythm. Sub-study 2 looks at how individuals metabolize melatonin. Sub-study 3 tests how individuals' endogenous melatonin production responds to bright outdoor light and Sub-study 4 tests a previous finding that artificial bright light exposed daily behind the knee can regulate the body clock. Sub-study 5 is an optional longitudinal study, an extension of the first study stage, for subjects whose rhythms are not clearly free-running.
Interventions
- DRUG Melatonin
- BEHAVIORAL Regular Sleep Schedule
- BEHAVIORAL Light
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 1997-06 |
| Est. Completion | 2012-06 |
| Phase | NA |
Why NCT00911053 stopped before completion
NCT00911053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Melatonin is the first listed.
NCT00911053 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00911053 about?
NCT00911053 is a clinical study titled "Melatonin for Circadian Sleep Disorders in the Blind". This research project consists of a three part study with five embedded sub studies. The first study phase identifies "body rhythms" of sleepiness/wakefulness and of melatonin levels for each subject (including sub-study 1). The second study phase identifies the optimum dose and timing of melatonin ...
What is the current status of trial NCT00911053?
This trial is currently terminated. It is a NA study. The enrollment target is 59 participants. The study started on 1997-06. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00911053?
The interventions under investigation include: Melatonin (DRUG), Regular Sleep Schedule (BEHAVIORAL), Light (BEHAVIORAL).
Who is sponsoring clinical trial NCT00911053?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00911053's enrollment target sits among peer trials
59 1256th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia